CA-CEQUENCE-SECURITY
10.9.2019 06:02:08 CEST | Business Wire | Press release
Cequence Security, a provider of innovative application security solutions for today’s hyper-connected enterprises, today advanced its global expansion with the opening of its EMEA headquarters in Munich, Germany, and the appointments of accomplished cybersecurity executives David Curran as Vice President, EMEA, and James Sherlow as Director of Solutions Engineering. The Cequence Application Security Platform (ASP), which consolidates multiple security functions and breakthrough innovations to protect web, mobile, and API-based applications, will be showcased at three important events:
- OWASP Global AppSec Conference in Amsterdam, September 26-27, 2019, where Cequence Chief Product Officer and Co-Founder Ameya Talwalkar will be featured as a speaker.
- ISMG Cybersecurity Summit in London, October 22, 2019, where Ameya Talwalkar will also be featured as a speaker.
- Aviation ISAC Summit in Barcelona, Spain, the global event for aviation cybersecurity, October 30-November 1, 2019, where Cequence Chief Technology Officer and Co-Founder Shreyans Mehta will be featured as a speaker.
The award-winning Cequence platform, designed to support today’s cloud-native, container-based applications, was most recently chosen over numerous contenders as “Startup of the Year” in security software by Network Products Guide. The company and platform have amassed seven recognitions and awards from peers, customers, and analysts since the platform’s launch in November 2018.
Global leaders in the retail, financial, consumer services, and social media sectors rely on Cequence ASP and its integrated modules to protect their web, mobile, and API-based application tier with unprecedented effectiveness. The CQ botDefense Module thwarts malicious bot attacks by using the patented CQAI analytics engine to detect and defend against automated attacks that appear to be legitimate. The CQ appFirewall module similarly employs CQAI to provide non-stop security, even with continuous application updates and modifications to production apps at scale by DevOps teams. It prevents attacks targeting web, mobile, and API-based applications, and helps eliminate unwanted application traffic on enterprise networks.
“Hyperconnected organizations across the EMEA region are leading today’s digital economy, and their Internet-facing applications and APIs are increasingly the targets of advanced semantic and syntactic attacks,” said David Curran, Cequence Vice President, EMEA. “Cequence ASP provides unprecedented protection against business logic abuse such as Account Takeover, Fake Accounts, Content Scraping, Denial of Inventory, Application-level DDoS, API Abuse, Gift Card Fraud, Click Fraud, and Aggregator Abuse. It’s game-changing technology and I’m honored by the opportunity to help strengthen the security posture of these organizations.”
Additional Resources:
David Curran, Vice President, EMEA – bio
James Sherlow, Director of Solutions Engineering, EMEA – bio
Cequence Security
About Cequence Security
Cequence Security is a venture-backed cybersecurity software company founded in 2015 and based in Sunnyvale, CA. Its mission is to transform application security by consolidating multiple innovative security functions within an open, AI-powered software platform that protects customers web, mobile, and API-based applications – and supports today’s cloud-native, container-based application architectures. The company is led by industry veterans that previously held leadership positions at Palo Alto Networks and Symantec. Customers include F500 organizations across multiple vertical markets, and the solution has earned multiple industry accolades, including 2018 Gartner Cool Vendor. Learn more at www.cequence.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909006012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
